Literature DB >> 16264344

Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis.

Robert C Sergott1.   

Abstract

PURPOSE OF REVIEW: This review considers the latest developments in the use of optical coherence tomography in neuro-ophthalmology. RECENT
FINDINGS: Optical coherence tomography can accurately and reproducibly quantitate the micron thickness of the peripapillary retinal nerve fiber layer, as well as the thickness and volume of the macula. It is able to perform both cross-sectional and longitudinal studies in patients with multiple sclerosis and optic neuritis. It is able to measure and assess axonal preservation and protection when used in clinical trials.
SUMMARY: Specific guidelines when undertaking optical coherence tomography analyses for patients with multiple sclerosis and optic neuritis are needed to ensure uniformity among clinical trials; this development would be similar to the parameters devised when magnetic resonance imaging emerged as an important technology.

Entities:  

Mesh:

Year:  2005        PMID: 16264344     DOI: 10.1097/01.icu.0000188705.67815.0e

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  11 in total

1.  A study of retinal parameters measured by optical coherence tomography in patients with multiple sclerosis.

Authors:  Sai-Jing Hu; Yi-An You; Yi Zhang
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

2.  Retinal architecture and mfERG: Optic nerve head component response characteristics in MS.

Authors:  Zane S Schnurman; Teresa C Frohman; Shin C Beh; Darrel Conger; Amy Conger; Shiv Saidha; Steven Galetta; Peter A Calabresi; Ari J Green; Laura J Balcer; Elliot M Frohman
Journal:  Neurology       Date:  2014-04-30       Impact factor: 9.910

3.  Agreement between retinal nerve fiber layer measures from Spectralis and Cirrus spectral domain OCT.

Authors:  Nimesh B Patel; Joe L Wheat; Aldon Rodriguez; Victoria Tran; Ronald S Harwerth
Journal:  Optom Vis Sci       Date:  2012-05       Impact factor: 1.973

4.  Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials.

Authors:  John L Keltner; Kimberly E Cello; Laura J Balcer; Peter A Calabresi; Clyde E Markowitz; John S Werner
Journal:  Neuroophthalmology       Date:  2011-03-20

5.  Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.

Authors:  Venu Talla; Vittorio Porciatti; Vince Chiodo; Sanford L Boye; William W Hauswirth; John Guy
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-11       Impact factor: 4.799

6.  Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship.

Authors:  Alexander Klistorner; H Arvind; T Nguyen; R Garrick; M Paine; S Graham; J O'Day; C Yiannikas
Journal:  Doc Ophthalmol       Date:  2008-09-09       Impact factor: 2.379

7.  Gene Therapy with Single-Subunit Yeast NADH-Ubiquinone Oxidoreductase (NDI1) Improves the Visual Function in Experimental Autoimmune Encephalomyelitis (EAE) Mice Model of Multiple Sclerosis (MS).

Authors:  Venu Talla; Rajeshwari Koilkonda; John Guy
Journal:  Mol Neurobiol       Date:  2020-01-03       Impact factor: 5.590

8.  The relationship between visual field and retinal nerve fiber layer measurements in patients with multiple sclerosis.

Authors:  Han Cheng; Michal Laron; Jade S Schiffman; Rosa A Tang; Laura J Frishman
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-12       Impact factor: 4.799

9.  Optical coherence tomography versus visual evoked potentials in detecting subclinical visual impairment in multiple sclerosis.

Authors:  M Grecescu
Journal:  J Med Life       Date:  2014 Oct-Dec

10.  Ability of Swept-Source Optical Coherence Tomography to Detect Retinal and Choroidal Changes in Patients with Multiple Sclerosis.

Authors:  Elena Garcia-Martin; Laura Jarauta; Elisa Vilades; Jose Ramon Ara; Jesus Martin; Vicente Polo; Jose Manuel Larrosa; Luis Emilio Pablo; Maria Satue
Journal:  J Ophthalmol       Date:  2018-11-13       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.